دورية أكاديمية

Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review

التفاصيل البيبلوغرافية
العنوان: Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review
المؤلفون: Illari Sechi, Narcisa Muresu, Biagio Di Lorenzo, Laura Saderi, Mariangela Puci, Stefano Aliberti, Ivana Maida, Michele Mondoni, Andrea Piana, Giovanni Sotgiu
المصدر: Infectious Disease Reports, Vol 16, Iss 2, Pp 200-215 (2024)
بيانات النشر: MDPI AG, 2024.
سنة النشر: 2024
المجموعة: LCC:Other systems of medicine
مصطلحات موضوعية: recurrent respiratory papillomatosis, HPV, lung cancer, lung involvement, pulmonary involvement, Other systems of medicine, RZ201-999
الوصف: Recurrent respiratory papillomatosis (RRP) is a non-malignant disease, characterized by the production of wart-like growths in the respiratory tract, affecting both young people and adults (juvenile-onset recurrent respiratory papillomatosis, JORRP, and adult-onset recurrent respiratory papillomatosis, AORRP, respectively). Infection caused by human papillomavirus (HPV) is known as the main factor involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation. The present systematic review aimed to evaluate the prevalence of severe complications, such as lung involvement and lung tumor in JORRP and AORRP patients, and assess the role of HPV genotypes in the progression of disease severity following the guideline for reporting systematic reviews and meta-analysis (PRISMA Statement). A total of 378 studies were found on PubMed and Scopus using the following MESH terms: “recurrent respiratory papillomatosis and lung tumor” and “pulmonary tumor and recurrent respiratory papillomatosis”. Basing on inclusion and exclusion criteria, a total of 11 studies were included in the systematic review. We found a pooled prevalence of 8% (95% CI: 4–14%; I2: 87.5%) for lung involvement in RRP patients. In addition, we found a pooled risk difference of 5% in lung involvement between JORRP and AORRP (95% CI: −7–18%; I2: 85.6%, p-value: 0.41). Among patients with lung involvement, we observed a pooled prevalence of lung tumor of 4% (95% CI:1–7%; I2: 67.1%) and a pooled prevalence mortality for this group of 4% (95% CI:2–6%; I2: 0%). Overall, the positivity rate for HPV-6 and -11 in patients with RRP was 91%. Considering only cases with pulmonary involvement, the pooled prevalence for HPV-11 was 21% (95% CI: 5–45%; I2: 77.2%). Our results evidenced a low/middle risk of pulmonary involvement and lung tumor in JORRP and AORRP patients, with an increased risk for HPV-11-positive patients. Further studies should be performed to improve knowledge and adopt preventive measures to contrast the progression to severe diseases in RRP patients.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2036-7449
Relation: https://www.mdpi.com/2036-7449/16/2/16; https://doaj.org/toc/2036-7449
DOI: 10.3390/idr16020016
URL الوصول: https://doaj.org/article/9054dac903bf4cb69cb7b5bd00969c98
رقم الأكسشن: edsdoj.9054dac903bf4cb69cb7b5bd00969c98
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20367449
DOI:10.3390/idr16020016